Table 3

Female to male ratios in NMOSD cohorts

Author (reference)PopulationInclusion criteriaNFemale (%)Male (%)Ratio (F:M)
Asian
Nagaishi et al 201129 JapanAQP4-Ab positive583533 (91)50 (9)10.7:1
Barhate et al 201430 India2006 Wingerchuk8 4439 (89)5 (11)7.8:1
Pandit and Kundapur 201431 India2006/2007 Wingerchuk4 116 (55)5 (45)1.2:1
Yin et al 201532 China2006 Wingerchuk plus*10892 (85)16 (15)5.8:1
Black
Flanagan et al 201618 USA/MartiniqueAQP4-Ab positive4540 (89)5 (11)8:1
Daoudi and Bouzar 201633 Algeria2015 Wingerchuk11 86 (75)2 (25)3:1
Caucasian
Rivera et al 200834 Mexico1999 Wingerchuk35 3424 (71)10 (29)2.4:1
Cabrera-Gómez et al 200924 Cuba1999 Wingerchuk5851 (88)7 (12)7.3:1
Asgari et al 201119 Denmark2006 Wingerchuk4231 (74)11 (26)2.8:1
Collongues et al 201136 France2006 Wingerchuk155108 (70)47 (30)2.3:1
Cossburn et al 201225 Wales2007 Wingerchuk1412 (86)2 (14)6:1
Aboul-Enein et al 201337 AustriaAQP4-Ab positive7162 (87)9 (13)6.9:1
Jacob et al 201326 England2006 Wingerchuk87 (88)1 (13)7:1
Etemadifar et al 201427 Iran2006 Wingerchuk9566 (69)29 (31)2.3:1
Kashipazha et al 201528 Iran2006 Wingerchuk plus†3630 (83)6 (17)5:1
Chitnis et al 201638 USA‡2006 Wingerchuk plus¶3826 (68)12 (32)2.2:1
Sepúlveda et al 201639 Spain2006 Wingerchuk181157 (87)24 (13)6.5:1
Kleiter et al 201640 Germany2006 Wingerchuk plus*186152 (82)34 (18)4.5:1
Present studyANZ2015 Wingerchuk147126 (86)21 (14)6:1
Combined18641568 (84)296 (16)5.3:1
  • *Additional criteria included AQP4-Ab positive high-risk syndromes. 41

  • Additional criteria included those suggested by Lana-Piexoto & Callegaro.42

  • ‡Paediatric population.

  • ¶Additional criteria included expert panel review.

  • NMOSD, neuromyelitis optica spectrum disorder.